The resolution of a dispute between Germany's health ministry and health care reimbursement authority has restarted the country's plan for expedited approval of medtech devices that show great promise but still lack evidence from clinical trials. The dispute between the two agencies centered on definitions of "success" and a payback scheme for industry applicants that has now been dropped.
Delays in German medtech fast-tracking ending
SmartBrief Job Listings for Health Care
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Chief, Product Review Branch||
FDA/Center for Biologics Evaluation and Research
|Silver Spring, MD|
|Director of Clinical Research||
Regenesis Biomedical, Inc.